KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions for authors
- Article processing charge
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
Original Articles
- Complications
- Risk of End-Stage Kidney Disease in Individuals with Diabetes Living Alone: A Large-Scale Population-Based Study
- Kyunghun Sung, Jae-Seung Yun, Bongseong Kim, Hun-Sung Kim, Jae-Hyoung Cho, Yong-Moon Mark Park, Kyungdo Han, Seung-Hwan Lee
- Received September 20, 2024 Accepted December 12, 2024 Published online April 5, 2025
- DOI: https://doi.org/10.4093/dmj.2024.0578 [Epub ahead of print]
- 593 View
- 30 Download
-
Abstract
PDF
Supplementary Material
PubReader 
ePub - Background
Previous research has linked solitary living to various adverse health outcomes, but its association with diabetic complications among individuals with type 2 diabetes mellitus (T2DM) remains underexplored. We examined the risk of endstage kidney disease (ESKD) in individuals with diabetes living alone (IDLA).
Methods
This population-based cohort study used the National Health Information Database of Korea, which included 2,432,613 adults with T2DM. Household status was determined based on the number of registered family members. IDLA was defined as continuously living alone for 5 years or more. A multivariable Cox proportional hazards model was used to evaluate the association between living alone and the risk of developing ESKD.
Results
During a median follow-up of 6.0 years, 26,691 participants developed ESKD, with a higher incidence observed in the IDLA group than in the non-IDLA group. After adjusting for confounding variables, the hazard ratio for ESKD in the IDLA group was 1.10 (95% confidence interval, 1.06 to 1.14). The risk of ESKD was particularly elevated in younger individuals, those without underlying chronic kidney disease, with longer durations of living alone, and with low household income. Adherence to favorable lifestyle behaviors (no smoking, no alcohol consumption, and engaging in regular exercise) was associated with a significantly lower risk of ESKD, with a more pronounced effect in the IDLA group.
Conclusion
Living alone was associated with a higher risk of ESKD in individuals with T2DM. Tailored medical interventions and social support for IDLA are crucial for the prevention of diabetic complications.
- Complications
- Burden of End-Stage Kidney Disease by Type 2 Diabetes Mellitus Status in South Korea: A Nationwide Epidemiologic Study
- Jwa-Kyung Kim, Han Na Jung, Bum Jun Kim, Boram Han, Ji Hye Huh, Eun Roh, Joo-Hee Kim, Kyung-Do Han, Jun Goo Kang
- Diabetes Metab J. 2025;49(3):498-506. Published online March 6, 2025
- DOI: https://doi.org/10.4093/dmj.2024.0443
- 696 View
- 38 Download
-
Abstract
PDFPubReader ePub
- Background
Patients with diabetes are known to be at high risk for end-stage kidney disease (ESKD), but the accurate annual risk data for new-onset ESKD is still limited. In South Korea, the prevalence and incidence of ESKD are increasing more rapidly compared to the global average. This study aimed to determine the incidence rate (IR) of ESKD by diabetes status from 2012 to 2022.
Methods
Using data from the Korean National Health Insurance Service, we calculated the IR and hazard ratio (HR) for newonset ESKD in the general population. Individuals were categorized based on diabetes status into nondiabetes, impaired fasting glucose (IFG), diabetes duration <5 and ≥5 years.
Results
Among the participants, 67.6% were nondiabetic, 22.3% had IFG, and 10% had diabetes. In Korea, the IRs of ESKD were 139 per million population (pmp) for nondiabetes, 188 pmp for IFG, 632 pmp for diabetes <5 years, and 3,403 pmp for diabetes ≥5 years. An advanced estimated glomerular filtration rate (eGFR) category was the strongest risk factor for ESKD development. However, even in patients with normal renal function, those with long-standing diabetes had a 14-fold higher risk of ESKD compared to nondiabetic individuals. The risk of ESKD associated with diabetes increased exponentially with declining renal function. Notably, IFG showed an increasing tendency for ESKD in younger patients (<65 years) with early-stage chronic kidney disease (CKD; eGFR ≥60 mL/min/1.73 m²).
Conclusion
Longer diabetes duration amplifies ESKD risk, particularly as renal function declines. Even in patients with normal renal function, long-standing diabetes significantly increases ESKD risk, while IFG is associated with elevated risk only in younger individuals with early-stage CKD.
- Basic and Translational Research
- Revealing VCAN as a Potential Common Diagnostic Biomarker of Renal Tubules and Glomerulus in Diabetic Kidney Disease Based on Machine Learning, Single-Cell Transcriptome Analysis and Mendelian Randomization
- Li Jiang, Jie Jian, Xulin Sai, Xiai Wu
- Diabetes Metab J. 2025;49(3):407-420. Published online January 24, 2025
- DOI: https://doi.org/10.4093/dmj.2024.0233
- 1,794 View
- 185 Download
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Diabetic kidney disease (DKD) is recognized as a significant complication of diabetes mellitus and categorized into glomerular DKDs and tubular DKDs, each governed by distinct pathological mechanisms and biomarkers.
Methods
Through the identification of common features observed in glomerular and tubular lesions in DKD, numerous differentially expressed gene were identified by the machine learning, single-cell transcriptome and mendelian randomization.
Results
The diagnostic markers versican (VCAN) was identified, offering supplementary options for clinical diagnosis. VCAN significantly highly expressed in glomerular parietal epithelial cell and proximal convoluted tubular cell. It was mainly involved in the up-regulation of immune genes and infiltration of immune cells like mast cell. Mendelian randomization analysis confirmed that serum VCAN protein levels were a risky factor for DKD, while there was no reverse association. It exhibited the good diagnostic potential for estimated glomerular filtration rate and proteinuria in DKD.
Conclusion
VCAN showed the prospects into DKD pathology and clinical indicator.
- Pharmacotherapy
- Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)
- Nam Hoon Kim, Soo Lim, In-Kyung Jeong, Eun-Jung Rhee, Jun Sung Moon, Ohk-Hyun Ryu, Hyuk-Sang Kwon, Jong Chul Won, Sang Soo Kim, Sang Yong Kim, Bon Jeong Ku, Heung Yong Jin, Sin Gon Kim, Bong-Soo Cha, on Behalf of Investigators of ENVELOP Study
- Diabetes Metab J. 2025;49(2):225-234. Published online January 6, 2025
- DOI: https://doi.org/10.4093/dmj.2024.0238
- 2,870 View
- 167 Download
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated.
Methods
This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged ≥19 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular or renal events (Clinical Research Information Service registration number: KCT0009243).
Conclusion
This trial will determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with T2DM and cardiovascular risk factors. This study will elucidate the role of enavogliflozin in preventing vascular complications in patients with T2DM.
- Basic research
- Reducing Oxidative Stress and Inflammation by Pyruvate Dehydrogenase Kinase 4 Inhibition Is Important in Prevention of Renal Ischemia-Reperfusion Injury in Diabetic Mice
- Ah Reum Khang, Dong Hun Kim, Min-Ji Kim, Chang Joo Oh, Jae-Han Jeon, Sung Hee Choi, In-Kyu Lee
- Diabetes Metab J. 2024;48(3):405-417. Published online February 1, 2024
- DOI: https://doi.org/10.4093/dmj.2023.0196
- 5,759 View
- 362 Download
- 6 Web of Science
- 6 Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Reactive oxygen species (ROS) and inflammation are reported to have a fundamental role in the pathogenesis of ischemia-reperfusion (IR) injury, a leading cause of acute kidney injury. The present study investigated the role of pyruvate dehydrogenase kinase 4 (PDK4) in ROS production and inflammation following IR injury.
Methods
We used a streptozotocin-induced diabetic C57BL6/J mouse model, which was subjected to IR by clamping both renal pedicles. Cellular apoptosis and inflammatory markers were evaluated in NRK-52E cells and mouse primary tubular cells after hypoxia and reoxygenation using a hypoxia work station.
Results
Following IR injury in diabetic mice, the expression of PDK4, rather than the other PDK isoforms, was induced with a marked increase in pyruvate dehydrogenase E1α (PDHE1α) phosphorylation. This was accompanied by a pronounced ROS activation, as well as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and monocyte chemoattractant protein-1 (MCP-1) production. Notably, sodium dichloroacetate (DCA) attenuated renal IR injury-induced apoptosis which can be attributed to reducing PDK4 expression and PDHE1α phosphorylation levels. DCA or shPdk4 treatment reduced oxidative stress and decreased TNF-α, IL-6, IL-1β, and MCP-1 production after IR or hypoxia-reoxygenation injury.
Conclusion
PDK4 inhibition alleviated renal injury with decreased ROS production and inflammation, supporting a critical role for PDK4 in IR mediated damage. This result indicates another potential target for reno-protection during IR injury; accordingly, the role of PDK4 inhibition needs to be comprehensively elucidated in terms of mitochondrial function during renal IR injury. -
Citations
Citations to this article as recorded by
- Persistent subclinical renal injury in female rats following renal ischemia-reperfusion injury
Desmond Moronge, Hannah Godley, Victor Ayulo, Elisabeth Mellott, Mona Elgazzaz, Gibson Cooper, Riyaz Mohamed, Safia Ogbi, Ellen Gillis, Jessica L. Faulkner, Jennifer C. Sullivan
Clinical Science.2025; 139(04): 309. CrossRef - Edaravone dexborneol exerts anti-epileptic effects on rodent temporal lobe epilepsy by promoting NMDAR deactivation and inhibiting oxidative stress
Wanhua Qiu, Roumeng Chen, Lechen Pan, Yiqian Li, Yuchen Xu, Yuqian Li, Ang Guo, Wenting Huang, Tao Tan, Peijun Li, Chenglong Xie, Huiqin Xu, Li Lin, Xinshi Wang
Phytomedicine.2025; 140: 156558. CrossRef - Cardiac PDK4 promotes neutrophilic PFKL methylation and drives the innate immune response in diabetic myocardial infarction
Song Yang, Longxin Yan, Lang Chen, Gaijuan Su, Long Yang, Lili Gong, Lihong Liu
Pharmacological Research.2025; 215: 107731. CrossRef - Exploring Renal Pyruvate Metabolism as a Therapeutic Avenue for Diabetic Kidney Injury
Jaemin Lee
Diabetes & Metabolism Journal.2024; 48(3): 385. CrossRef - Cardiovascular Disease and miRNAs: Possible Oxidative Stress-Regulating Roles of miRNAs
Seahyoung Lee
Antioxidants.2024; 13(6): 656. CrossRef - Sodium Phenylbutyrate Attenuates Cisplatin-Induced Acute Kidney Injury Through Inhibition of Pyruvate Dehydrogenase Kinase 4
Chang Joo Oh, Wooyoung Choi, Ha Young Lee, In-Kyu Lee, Min-Ji Kim, Jae-Han Jeon
Biomedicines.2024; 12(12): 2815. CrossRef
- Persistent subclinical renal injury in female rats following renal ischemia-reperfusion injury
Review
- Others
- Risk Prediction and Management of Chronic Kidney Disease in People Living with Type 2 Diabetes Mellitus
- Ying-Guat Ooi, Tharsini Sarvanandan, Nicholas Ken Yoong Hee, Quan-Hziung Lim, Sharmila S. Paramasivam, Jeyakantha Ratnasingam, Shireene R. Vethakkan, Soo-Kun Lim, Lee-Ling Lim
- Diabetes Metab J. 2024;48(2):196-207. Published online January 26, 2024
- DOI: https://doi.org/10.4093/dmj.2023.0244
- 6,083 View
- 591 Download
- 1 Web of Science
- 2 Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- People with type 2 diabetes mellitus have increased risk of chronic kidney disease and atherosclerotic cardiovascular disease. Improved care delivery and implementation of guideline-directed medical therapy have contributed to the declining incidence of atherosclerotic cardiovascular disease in high-income countries. By contrast, the global incidence of chronic kidney disease and associated mortality is either plateaued or increased, leading to escalating direct and indirect medical costs. Given limited resources, better risk stratification approaches to identify people at risk of rapid progression to end-stage kidney disease can reduce therapeutic inertia, facilitate timely interventions and identify the need for early nephrologist referral. Among people with chronic kidney disease G3a and beyond, the kidney failure risk equations (KFRE) have been externally validated and outperformed other risk prediction models. The KFRE can also guide the timing of preparation for kidney replacement therapy with improved healthcare resources planning and may prevent multiple complications and premature mortality among people with chronic kidney disease with and without type 2 diabetes mellitus. The present review summarizes the evidence of KFRE to date and call for future research to validate and evaluate its impact on cardiovascular and mortality outcomes, as well as healthcare resource utilization in multiethnic populations and different healthcare settings.
-
Citations
Citations to this article as recorded by- A Machine Learning-Based Prediction Model for Diabetic Kidney Disease in Korean Patients with Type 2 Diabetes Mellitus
Kyung Ae Lee, Jong Seung Kim, Yu Ji Kim, In Sun Goak, Heung Yong Jin, Seungyong Park, Hyejin Kang, Tae Sun Park
Journal of Clinical Medicine.2025; 14(6): 2065. CrossRef - Prevalence of diabetes and its associated factors in Cape Verde: an analysis of the 2020 WHO STEPS survey on non-communicable diseases risk factors
Joshua Okyere, Castro Ayebeng, Kwamena Sekyi Dickson
BMC Endocrine Disorders.2024;[Epub] CrossRef
- A Machine Learning-Based Prediction Model for Diabetic Kidney Disease in Korean Patients with Type 2 Diabetes Mellitus
Original Article
- Drug/Regimen
- Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis
- Min-Hsiang Chuang, Yu-Shuo Tang, Jui-Yi Chen, Heng-Chih Pan, Hung-Wei Liao, Wen-Kai Chu, Chung-Yi Cheng, Vin-Cent Wu, Michael Heung
- Diabetes Metab J. 2024;48(2):242-252. Published online January 26, 2024
- DOI: https://doi.org/10.4093/dmj.2023.0201
- 5,227 View
- 412 Download
- 1 Web of Science
- 1 Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
The initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) typically leads to a reversible initial dip in estimated glomerular filtration rate (eGFR). The implications of this phenomenon on clinical outcomes are not well-defined.
Methods
We searched MEDLINE, Embase, and Cochrane Library from inception to March 23, 2023 to identify randomized controlled trials and cohort studies comparing kidney and cardiovascular outcomes in patients with and without initial eGFR dip after initiating SGLT2i. Pooled estimates were calculated using random-effect meta-analysis.
Results
We included seven studies in our analysis, which revealed that an initial eGFR dip following the initiation of SGLT2i was associated with less annual eGFR decline (mean difference, 0.64; 95% confidence interval [CI], 0.437 to 0.843) regardless of baseline eGFR. The risk of major adverse kidney events was similar between the non-dipping and dipping groups but reduced in patients with a ≤10% eGFR dip (hazard ratio [HR], 0.915; 95% CI, 0.865 to 0.967). No significant differences were observed in the composite of hospitalized heart failure and cardiovascular death (HR, 0.824; 95% CI, 0.633 to 1.074), hospitalized heart failure (HR, 1.059; 95% CI, 0.574 to 1.952), or all-cause mortality (HR, 0.83; 95% CI, 0.589 to 1.170). The risk of serious adverse events (AEs), discontinuation of SGLT2i due to AEs, kidney-related AEs, and volume depletion were similar between the two groups. Patients with >10% eGFR dip had increased risk of hyperkalemia compared to the non-dipping group.
Conclusion
Initial eGFR dip after initiating SGLT2i might be associated with less annual eGFR decline. There were no significant disparities in the risks of adverse cardiovascular outcomes between the dipping and non-dipping groups. -
Citations
Citations to this article as recorded by- Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors
Birdie Huang, Yi-Wei Kao, Kun-Chi Yen, Shao-Wei Chen, Tze-Fan Chao, Yi-Hsin Chan
The Journal of Clinical Endocrinology & Metabolism.2025;[Epub] CrossRef
- Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors
Review
- Complications
- Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
- Sang Heon Suh, Soo Wan Kim
- Diabetes Metab J. 2023;47(5):612-629. Published online July 24, 2023
- DOI: https://doi.org/10.4093/dmj.2023.0067
- 14,941 View
- 1,049 Download
- 25 Web of Science
- 27 Crossref
-
Abstract
PDFPubReader ePub
- Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes clinical practice guideline for lipid management in chronic kidney disease (CKD) presented a relatively conservative approach with respect to the indication of lipid lowering therapy and therapeutic monitoring among the patients with CKD. This may be largely attributed to the lack of high-quality evidence derived from CKD population, among whom the overall feature of dyslipidemia is considerably distinctive to that of general population. In this review article, we cover the characteristic features of dyslipidemia and impact of dyslipidemia on cardiovascular outcomes in patients with CKD. We also review the current evidence on lipid lowering therapy to modify the risk of cardiovascular events in this population. We finally discuss the association between dyslipidemia and CKD progression and the potential strategy to delay the progression of CKD in relation to lipid lowering therapy.
-
Citations
Citations to this article as recorded by- Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study
Zhongchen Li, Chunyu Yu, Heng Zhang, Runze Chen, Yan Zhao, Zhe Zheng
Cardiovascular Diabetology.2025;[Epub] CrossRef - Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial
Liana Trugilho, Lívia Alvarenga, Ludmila Cardozo, Bruna Paiva, Jessyca Brito, Isis Barboza, Jonatas Almeida, Juliana dos Anjos, Pramod Khosla, Marcelo Ribeiro-Alves, Denise Mafra, Eric Gumpricht
Journal of Nutrition and Metabolism.2025;[Epub] CrossRef - The Impact of Glomerular Disease on Dyslipidemia in Pediatric Patients Treated with Dialysis
Edward Zitnik, Elani Streja, Marciana Laster
Nutrients.2025; 17(3): 459. CrossRef - Diabetes, Chronic Kidney Disease, and Vascular Ulcers: Prevention Strategies and Clinical Implications
Stefano Mancin, Alfonso Zarrella, Fabio Petrelli, Simone Cosmai, Daniela Cattani, Diego Lopane, Sarah Scollo, Sara Morales Palomares, Marco Sguanci, Antonella Amendola, Giovanni Cangelosi, Beatrice Mazzoleni
Diabetology.2025; 6(2): 10. CrossRef - Cardiovascular disease burden and associated risk factors in chronic kidney disease
Roshan Bhandari, Srijan Pantha, Ghanashyam Pandey, Richa Paudyal
Indian Journal of Medical Sciences.2025; 0: 1. CrossRef - Association of the Triglyceride-Glucose Index with Body Composition and Laboratory Parameters in Chronic Kidney Disease Stages 3–5
Shan-Shan Xu, Yan-Meng Guan, Hong-Yun Xuan, Xiu-Fang Fan, Ping Lu, Li-Hai Hao
Risk Management and Healthcare Policy.2025; Volume 18: 903. CrossRef - The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and pulmonary function: evidence from NHANES 2007–2012
Miaoyan Liu, Chaofeng Gao, Jinggeng Li, Yibo Zhang, Rui Gao, Chaoting Yang, Jian Zhang
Frontiers in Nutrition.2025;[Epub] CrossRef - Dietary butyric acid intake, kidney function, and survival: The National Health and Nutrition Examination Surveys, 2005–2018
Wei Tang, Zhengyi Long, Yang Xiao, Jingyun Du, Chenyuan Tang, JunXiang Chen, Can Hou
Clinical Nutrition ESPEN.2025; 67: 453. CrossRef - From fat to filter: the effect of adipose tissue-derived signals on kidney function
Nermin Ahmed, Carolina Dalmasso, Meghan B. Turner, Gertrude Arthur, Cole Cincinelli, Analia S. Loria
Nature Reviews Nephrology.2025;[Epub] CrossRef - CHANGES IN CENTRAL AORTIC PRESSURE AND ARTERIAL STIFFNESS IN YOUNG MEN WITH ARTERIAL HYPERTENSION AND CHRONIC KIDNEY DISEASE
O. M. Bilovol, I. I. Kniazkova, V. O. Golovachova, N. V. Kuzminova, D. О. Kіrienko, O. M. Kіrienko, L. P. Abramova
World of Medicine and Biology.2025; 21(91): 26. CrossRef - Analysis of the association between long-term exposure to low-dose ionizing radiation and dyslipidemia and its components in medical radiologists: The mediating role of inflammatory markers
Changyong Wen, Xiaolian Liu, Yiqing Lian, Weizhen Guo, Lingyu Zhang, Yanting Chen, Xin Lan, Mingfang Li, Sufen Zhang, Weixu Huang, Jianming Zou, Huifeng Chen
International Journal of Cardiology Cardiovascular Risk and Prevention.2025; 25: 200406. CrossRef - The protective effect of dietary sphingomyelin supplementation against impaired lipid metabolism in obese mice: a systematic review and meta-analysis of randomized controlled trials
Xiao-Yan Qin, Jie Pan, Yi-Na Liu, Hui-Min Luo, Fang Yang
Food, Nutrition and Health.2025;[Epub] CrossRef - Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications
Francesco Perone, Marco Bernardi, Luigi Spadafora, Matteo Betti, Stefano Cacciatore, Francesco Saia, Federica Fogacci, Vikash Jaiswal, Elad Asher, Francesco Paneni, Salvatore De Rosa, Maciej Banach, Giuseppe Biondi Zoccai, Pierre Sabouret
Journal of Cardiovascular Development and Disease.2025; 12(5): 171. CrossRef - Associations of cardiac biomarkers with chronic kidney disease and mortality in US individuals without prevalent cardiovascular disease
Haitao Xie, Shi Wang, Li Qian, Peng Yu, Xiaohu Chen, Shuhua Tang, Le Shen
Scientific Reports.2025;[Epub] CrossRef - Statin Therapy and Lipid Indices in Chronic Kidney Disease: A Systematic
Review and Meta-analysis of Randomized Control Trials
Jafar Karami, Bahman Razi, Danyal Imani, Saeed Aslani, Mahdi Pakjoo, Mahdieh Fasihi, Keyhan Mohammadi, Amirhossein Sahebkar
Current Pharmaceutical Design.2024; 30(5): 362. CrossRef - Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report
Junichiro Kato, Hideo Okonogi, Go Kanzaki, Haruki Katsumata, Yasuyuki Nakada, Makoto Sagasaki, Kazumasa Komine, Kenji Ito, Takao Saito, Akira Matsunaga, Koh Tokutou, Kazuho Honda, Nobuo Tsuboi, Takashi Yokoo
BMC Nephrology.2024;[Epub] CrossRef - Atherogenic index of plasma: a new indicator for assessing the short-term mortality of patients with acute decompensated heart failure
Meng Yu, Hongyi Yang, Maobin Kuang, Jiajun Qiu, Changhui Yu, Guobo Xie, Guotai Sheng, Yang Zou
Frontiers in Endocrinology.2024;[Epub] CrossRef - Association between lipid accumulation product index and chronic kidney disease: A systematic review and meta-analysis
Feixiang Wu, Chenmin Cui, Junping Wu, Yunqing Wang
Experimental and Therapeutic Medicine.2024;[Epub] CrossRef - Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease
Rabab Mahmoud Ahmed, Nehal Kamal Rakha, Ahmed Yousry, Amin Roshdy Soliman
The Egyptian Journal of Internal Medicine.2024;[Epub] CrossRef - Pulmonary Hypertension in Hemodialysis Patients and Its Determinants: A Hospital Based Cross-Sectional Study
Qingfei Yu, Qin Zhang
International Journal of General Medicine.2024; Volume 17: 3919. CrossRef - Relationship Between Serum Uromodulin as a Marker of Kidney Damage and Metabolic Status in Patients with Chronic Kidney Disease of Non-Diabetic Etiology
Radmila Žeravica, Branislava Ilinčić, Dragan Burić, Ana Jakovljević, Veljko Crnobrnja, Dalibor Ilić, Marija Vukmirović Papuga
International Journal of Molecular Sciences.2024; 25(20): 11159. CrossRef - Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes
Natalia Stepanova
Biomedicines.2024; 12(10): 2377. CrossRef - Causal associations between kidney function and aortic valve stenosis: a bidirectional Mendelian randomization analysis
Wanqian Pan, Le Zhou, Rui Han, Xiaojiao Du, Weixiang Chen, Tingbo Jiang
Renal Failure.2024;[Epub] CrossRef - U-shaped association between dietary niacin intake and chronic kidney disease among US elderly: a nationwide cross-sectional study
Zhouzhou Xie, Shansen Peng, Gejun Ou, Xiaoqi Zhou, Guihao Zhang, Huiming Jiang, Tianhui Zhang, Nanhui Chen
Frontiers in Endocrinology.2024;[Epub] CrossRef - Association between dried fruit intake and kidney function: research from univariate and multivariate Mendelian randomized studies
Yuhang Gao, Xinghai Yue, Wanchao Zhao, Fang Yuan
Frontiers in Nutrition.2024;[Epub] CrossRef - The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease
Alfredo Caturano, Raffaele Galiero, Maria Rocco, Giuseppina Tagliaferri, Alessia Piacevole, Davide Nilo, Giovanni Di Lorenzo, Celestino Sardu, Vincenzo Russo, Erica Vetrano, Marcellino Monda, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso
Biomolecules.2024; 14(11): 1393. CrossRef - Association between the EHBP1 SNPs and dyslipidemia in the end-stage renal disease patients with dialysis in Chinese Han population
Yan-Fei Lai, Zhong-E Liang, Chun-Xiang Wu, Min Zhang, Zong-Hu Shi, Xiao-Yan Meng, Chun-Xiao Liu
Lipids in Health and Disease.2024;[Epub] CrossRef
- Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study
Brief Reports
- Complications
- Trends in the Incidence, Prevalence, and Mortality of End-Stage Kidney Disease in South Korea
- Min-Jeong Lee, Kyoung Hwa Ha, Dae Jung Kim, Inwhee Park
- Diabetes Metab J. 2020;44(6):933-937. Published online December 23, 2020
- DOI: https://doi.org/10.4093/dmj.2020.0156
- 8,279 View
- 277 Download
- 19 Web of Science
- 22 Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Knowledge of the epidemiologic characteristics of end-stage kidney disease (ESKD) patients is essential. The trends in the prevalence, incidence, and mortality rates of ESKD were analyzed retrospectively using the Korean National Health Insurance ServiceNational Sample Cohort database between 2006 and 2015. From 2006 to 2015, the incidence of ESKD decreased from 28.6 to 24.0 per 100,000 people and showed a decreasing pattern with or without diabetes mellitus. However, the incidence of those aged ≥75 years increased, as did the mean age at the onset of ESKD. From 2007 to 2015, the prevalence of ESKD increased in all age groups, but particularly in those aged ≥75 years. The prevalence of ESKD differed by sex and diabetes mellitus status and this gap widened over time. Mortality rates in ESKD patients remained relatively constant throughout the study period. However, mortality rates in ESKD without diabetes decreased over the same period.
-
Citations
Citations to this article as recorded by- Risk factors and transitional probability of clinical events in Korean CKD patients using the multistate model
Ji Hye Kim, Jinheum Kim, Jayoun Kim, Ji Yong Jung, Jong Cheol Jeong, Seung Hyeok Han, Kook-Hwan Oh
Scientific Reports.2025;[Epub] CrossRef - Predicting renal function using fundus photography: role of confounders
Hyun-Woong Park, Hae Ri Kim, Ki Yup Nam, Bum Jun Kim, Taeseen Kang
The Korean Journal of Internal Medicine.2025; 40(2): 310. CrossRef - Burden of End-Stage Kidney Disease by Type 2 Diabetes Mellitus Status in South Korea: A Nationwide Epidemiologic Study
Jwa-Kyung Kim, Han Na Jung, Bum Jun Kim, Boram Han, Ji Hye Huh, Eun Roh, Joo-Hee Kim, Kyung-Do Han, Jun Goo Kang
Diabetes & Metabolism Journal.2025; 49(3): 498. CrossRef - Kidney Health Plan 2033 in Korea: bridging the gap between the present and the future
Do Hyoung Kim, Young Youl Hyun, Jin Joo Cha, Sua Lee, Hyun Kyung Lee, Jong Wook Choi, Su-Hyun Kim, Sang Youb Han, Cheol Whee Park, Eun Young Lee, Dae Ryong Cha, Sung Gyun Kim, Chun Soo Lim, Sun-Hee Park
Kidney Research and Clinical Practice.2024; 43(1): 8. CrossRef - Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: A nationwide population-based study
Soo Yeon Jang, Minwoong Kang, Eyun Song, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Diabetes Research and Clinical Practice.2024; 210: 111639. CrossRef - Effects of Kt/Vurea on outcomes according to age in patients on maintenance hemodialysis
Junseok Jeon, Gui Ok Kim, Bo Yeon Kim, Eun Jung Son, Jun Young Do, Jung Eun Lee, Seok Hui Kang
Clinical Kidney Journal.2024;[Epub] CrossRef - 2023 Diabetic Kidney Disease Fact Sheet in Korea
Nam Hoon Kim, Mi-Hae Seo, Jin Hyung Jung, Kyung Do Han, Mi Kyung Kim, Nan Hee Kim
Diabetes & Metabolism Journal.2024; 48(3): 463. CrossRef - Clinical Validation of a Mobile-Based ACR (Urine Albumin-to-Creatinine Ratio) Test Kit: Comparative Analysis with Benchtop Devices
Jiwon RYU, Eung-Kyu PARK, JunHyuck JANG, Dong-Hoon LEE
Korean Journal of Health Promotion.2024; 24(3): 118. CrossRef - Kidney replacement therapy trends in end-stage kidney disease patients in South Korea during the COVID-19 pandemic
Ah-Young Kim, Min-Jeong Lee, Heejung Choi, Hankil Lee, Inwhee Park
The Korean Journal of Internal Medicine.2024; 39(6): 967. CrossRef - Disparities in the Prevalence of Urinary Diseases Among Prisoners in Taiwan: Population-Based Cross-Sectional Study
Yen-Chun Wang, Zhu Liduzi Jiesisibieke, Yu-Pei Yang, Bing-Long Wang, Ming-Chon Hsiung, Tao-Hsin Tung
JMIR Public Health and Surveillance.2024; 10: e60136. CrossRef - Waist circumference and end‐stage renal disease based on glycaemic status: National Health Insurance Service data 2009–2018
Yun Kyung Cho, Ji Hye Huh, Shinje Moon, Yoon Jung Kim, Yang‐Hyun Kim, Kyung‐do Han, Jun Goo Kang, Seong Jin Lee, Sung‐Hee Ihm
Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 585. CrossRef - Usefulness of continuous glucose monitoring of blood glucose control in patients with diabetes undergoing hemodialysis: A pilot study
Sua Lee, Soyoung Lee, Kyeong Min Kim, Jong Ho Shin
Frontiers in Medicine.2023;[Epub] CrossRef - Association between N-Terminal Prohormone Brain Natriuretic Peptide and Decreased Skeletal Muscle Mass in a Healthy Adult Population: A Cross-Sectional Study
Tae Kyung Yoo, Marie Yung-Chen Wu, Moon Soo Kim, Mi-Yeon Lee, Yong-Taek Lee, Kyung Jae Yoon, Chul-Hyun Park
Endocrinology and Metabolism.2023; 38(2): 269. CrossRef - Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
Sun Ok Song, Eugene Han, Kang Ju Son, Bong-Soo Cha, Byung-Wan Lee
Journal of Clinical Medicine.2023; 12(9): 3160. CrossRef - Epigenome-wide association study of diabetic chronic kidney disease progression in the Korean population: the KNOW-CKD study
Hye Youn Sung, Sangjun Lee, Miyeun Han, Woo Ju An, Hyunjin Ryu, Eunjeong Kang, Yong Seek Park, Seung Eun Lee, Curie Ahn, Kook-Hwan Oh, Sue K. Park, Jung-Hyuck Ahn
Scientific Reports.2023;[Epub] CrossRef - Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Kieran F. Docherty, Inder S. Anand, Chern-En Chiang, Vijay K. Chopra, Akshay S. Desai, Masafumi Kitakaze, Subodh Verma, Pham N. Vinh, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S. Sabat
JACC: Asia.2022; 2(2): 139. CrossRef - Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine.2022; 37(3): 502. CrossRef - The risk of Parkinson's disease according to diabetic kidney disease status in a Korean population
Seung Eun Lee, Juhwan Yoo, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
Parkinsonism & Related Disorders.2022; 100: 13. CrossRef - Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
Nam Hoon Kim, Nan Hee Kim
Diabetes & Metabolism Journal.2022; 46(4): 543. CrossRef - The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study
Jun Hyoung Kim, Heeseon Jang, Jung Ho Kim, Joon Young Song, Shin-Woo Kim, Sang Il Kim, Bo Youl Choi, Jun Yong Choi
Infection & Chemotherapy.2022; 54(3): 534. CrossRef - Sex difference in the association among nutrition, muscle mass, and strength in peritoneal dialysis patients
Jun Young Do, Seok Hui Kang
Scientific Reports.2022;[Epub] CrossRef - Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk
Seohyun Kim, Gyuri Kim, Jae Hyeon Kim
Scientific Reports.2022;[Epub] CrossRef
- Risk factors and transitional probability of clinical events in Korean CKD patients using the multistate model
- Drug/Regimen
- Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
- Mi-Jin Kim, Na-young Kim, Yun-A Jung, Seunghyeong Lee, Gwon-Soo Jung, Jung-Guk Kim, In-Kyu Lee, Sungwoo Lee, Yeon-Kyung Choi, Keun-Gyu Park
- Diabetes Metab J. 2020;44(1):186-192. Published online October 31, 2019
- DOI: https://doi.org/10.4093/dmj.2018.0271
- 7,248 View
- 121 Download
- 10 Web of Science
- 10 Crossref
-
Abstract
PDFSupplementary MaterialPubReader
Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated protective effects against diabetic kidney disease. However, the anti-fibrotic effect of evogliptin, a DPP-4 inhibitor, has not been studied. Here, we report the beneficial effects of evogliptin on unilateral ureteral obstruction (UUO)-induced renal fibrosis in mice. Evogliptin attenuated UUO-induced renal atrophy and tubulointerstitial fibrosis. Immunohistochemistry and Western blotting demonstrated that evogliptin treatment inhibits pro-fibrotic gene expressions and extracellular matrix production.
In vitro findings showed that the beneficial effects of evogliptin on renal fibrosis are mediated by inhibition of the transforming growth factor-β/Smad3 signaling pathway. The present study demonstrates that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin.-
Citations
Citations to this article as recorded by- Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis
Birte Ohm, Isabelle Moneke, Wolfgang Jungraithmayr
British Journal of Pharmacology.2023; 180(22): 2846. CrossRef - Linagliptin ameliorates pulmonary fibrosis in systemic sclerosis mouse model via inhibition of endothelial-to-mesenchymal transition
Biwei Pei, Na Zhang, Tingting Pang, Gengyun Sun
Molecular and Cellular Biochemistry.2022; 477(4): 995. CrossRef - Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022. CrossRef - Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells
Hye-Young Seo, So-Hee Lee, Eugene Han, Jae Seok Hwang, Sol Han, Mi Kyung Kim, Byoung Kuk Jang
International Journal of Molecular Sciences.2022; 23(19): 11636. CrossRef - Optimization and validation of a fluorogenic dipeptidyl peptidase 4 enzymatic assay in human plasma
Hyunyee Yoon, Su Hee Cho, Yu Rim Seo, Kyung-Sang Yu, Sung Sup Park, Moon Jung Song
Analytical Biochemistry.2021; 612: 113952. CrossRef - Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside
Sungjin Chung, Gheun-Ho Kim
Life.2021; 11(5): 389. CrossRef - Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?
Xin Huang, Yimin Khoong, Chengyao Han, Dai Su, Hao Ma, Shuchen Gu, Qingfeng Li, Tao Zan
Frontiers in Physiology.2021;[Epub] CrossRef - Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
Gyuri Kim, Soo Lim, Hyuk‐Sang Kwon, Ie B. Park, Kyu J. Ahn, Cheol‐Young Park, Su K. Kwon, Hye S. Kim, Seok W. Park, Sin G. Kim, Min K. Moon, Eun S. Kim, Choon H. Chung, Kang S. Park, Mikyung Kim, Dong J. Chung, Chang B. Lee, Tae H. Kim, Moon‐Kyu Lee
Diabetes, Obesity and Metabolism.2020; 22(9): 1527. CrossRef Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Eugene Han, Minyoung Lee, Yong-ho Lee, Hye Soon Kim, Byung-wan Lee, Bong-Soo Cha, Eun Seok Kang
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4113. CrossRef- Efficacy and safety of novel dipeptidyl-peptidase-4 inhibitor evogliptin in the management of type 2 diabetes mellitus: A meta-analysis
Deep Dutta, Saptarshi Bhattacharya, Aishwarya Krishnamurthy, LokeshKumar Sharma, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2020; 24(5): 434. CrossRef
- Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis
Original Articles
- Basic Research
- Fibroblast Growth Factor 21 Attenuates Diabetes-Induced Renal Fibrosis by Negatively Regulating TGF-β-p53-Smad2/3-Mediated Epithelial-to-Mesenchymal Transition via Activation of AKT
- Sundong Lin, Lechu Yu, Yongqing Ni, Lulu He, Xiaolu Weng, Xuemian Lu, Chi Zhang
- Diabetes Metab J. 2020;44(1):158-172. Published online October 28, 2019
- DOI: https://doi.org/10.4093/dmj.2018.0235
- 7,593 View
- 127 Download
- 44 Web of Science
- 43 Crossref
-
Abstract
PDFSupplementary MaterialPubReader
Background Epithelial-to-mesenchymal transition (EMT) is required for renal fibrosis, which is a characteristic of diabetic nephropathy (DN). Our previous study demonstrated that fibroblast growth factor 21 (FGF21) prevented DN associated with the suppressing renal connective tissue growth factor expression, a key marker of renal fibrosis. Therefore, the effects of FGF21 on renal fibrosis in a DN mouse model and the underlying mechanisms were investigated in this study.
Methods Type 1 diabetes mellitus was induced in C57BL/6J mice by intraperitoneal injections of multiple low doses of streptozotocin. Then, diabetic and non-diabetic mice were treated with or without FGF21 in the presence of pifithrin-α (p53 inhibitor) or 10-[4′-(N,N-Diethylamino)butyl]-2-chlorophenoxazine hydrochloride (10-DEBC) hydrochloride (Akt inhibitor) for 4 months.
Results DN was diagnosed by renal dysfunction, hypertrophy, tubulointerstitial lesions, and glomerulosclerosis associated with severe fibrosis, all of which were prevented by FGF21. FGF21 also suppressed the diabetes-induced renal EMT in DN mice by negatively regulating transforming growth factor beta (TGF-β)-induced nuclear translocation of Smad2/3, which is required for the transcription of multiple fibrotic genes. The mechanistic studies showed that FGF21 attenuated nuclear translocation of Smad2/3 by inhibiting renal activity of its conjugated protein p53, which carries Smad2/3 into the nucleus. Moreover pifithrin-α inhibited the FGF21-induced preventive effects on the renal EMT and subsequent renal fibrosis in DN mice. In addition, 10-DEBC also blocked FGF21-induced inhibition of renal p53 activity by phosphorylation of mouse double minute-2 homolog (MDM2).
Conclusion FGF21 prevents renal fibrosis via negative regulation of the TGF-β/Smad2/3-mediated EMT process by activation of the Akt/MDM2/p53 signaling pathway.
-
Citations
Citations to this article as recorded by- RhFGF21 protected PC12 cells against mitochondrial apoptosis triggered by H2O2 via the AKT-mediated ROS signaling pathway
Jingjing Lin, Junyi Wu, Yifan Xu, Yeli Zhao, Shasha Ye
Experimental Cell Research.2025; 445(1): 114417. CrossRef - Airway stenosis: classification, pathogenesis, and clinical management
Pengwei Zhao, Zheng Jiang, Xuexin Li, Mailudan Ainiwaer, Leyu Li, Dejuan Wang, Lixiao Fan, Fei Chen, Jun Liu
MedComm.2025;[Epub] CrossRef - FGF21 Signaling Exerts Antifibrotic Properties during Pulmonary Fibrosis
Mada Ghanem, Gabrielle Archer, Aurélien Justet, Madeleine Jaillet, Eirini Vasarmidi, Pierre Mordant, Yves Castier, Hervé Mal, Aurélie Cazes, Nicolas Poté, Bruno Crestani, Arnaud Mailleux
American Journal of Respiratory and Critical Care Medicine.2025; 211(3): 486. CrossRef - Nucleic acid coated photothermal nanoregulator for multiple therapy of drug-resistant breast cancer
Yuxin Shen, Yixin Wen, Sen Li, Xuefeng Ding, Yanfei Cai, Jian Jin, Zhaoqi Yang
International Journal of Biological Macromolecules.2025; 308: 142592. CrossRef - Epithelial–mesenchymal plasticity in kidney fibrosis
Sudarat Hadpech, Visith Thongboonkerd
genesis.2024;[Epub] CrossRef - Fibroblast growth factor 21 alleviates unilateral ureteral obstruction-induced renal fibrosis by inhibiting Wnt/β-catenin signaling pathway
Wenhui Zhong, Yuheng Jiang, Huizhen Wang, Xiang Luo, Tao Zeng, Huimi Huang, Ling Xiao, Nan Jia, Aiqing Li
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2024; 1871(2): 119620. CrossRef - MAP3K19 Promotes the Progression of Tuberculosis-Induced Pulmonary Fibrosis Through Activation of the TGF-β/Smad2 Signaling Pathway
Yu Xia, Haiyue Wang, Meihua Shao, Xuemei Liu, Feng Sun
Molecular Biotechnology.2024; 66(11): 3300. CrossRef - Platelet concentrates may affect the formation of pathological scars by regulating epithelial to mesenchymal transition
Ju Tian, Dandan Shi, Chenyan Long, Jing Ding, Huimin You, Xiaoying He, Biao Cheng
Medical Hypotheses.2024; 182: 111227. CrossRef - Cadherin-responsive hydrogel combined with dental pulp stem cells and fibroblast growth factor 21 promotes diabetic scald repair via regulating epithelial-mesenchymal transition and necroptosis
Wenjie Lu, Juan Zhao, Xiong Cai, Yutian Wang, Wenwei Lin, Yaoping Fang, Yunyang Wang, Jinglei Ao, Jiahui Shou, Jiake Xu, Sipin Zhu
Materials Today Bio.2024; 24: 100919. CrossRef - Sodium butyrate ameliorated diabetic nephropathy-associated tubulointerstitial inflammation by modulating the tight junctions of renal tubular epithelial cells
Tingting Yang, Lin Li, Cai Heng, Pian Sha, Yiying Wang, Jiaming Shen, Zhenzhou Jiang, Sitong Qian, Chujing Wei, Hao Yang, Xia Zhu, Tao Wang, Mengying Wu, Jianyun Wang, Qian Lu, Xiaoxing Yin
Food & Function.2024; 15(5): 2628. CrossRef - Urinary Excretion of Biomolecules Related to Cell Cycle, Proliferation, and Autophagy in Subjects with Type 2 Diabetes and Chronic Kidney Disease
Anton I. Korbut, Vyacheslav V. Romanov, Vadim V. Klimontov
Biomedicines.2024; 12(3): 487. CrossRef - FGF21 Inhibits Hypoxia/Reoxygenation-induced Renal Tubular Epithelial Cell Injury by Regulating the PPARγ/NF-κB Signaling Pathway
Ruixue Li, Xi Liu
Cell Biochemistry and Biophysics.2024; 82(2): 909. CrossRef - Advances in the Treatment of Kidney Disorders using Mesenchymal Stem Cells
Shivam Rajput, Rishabha Malviya, Prerna Uniyal
Current Pharmaceutical Design.2024; 30(11): 825. CrossRef - The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?
Mada Ghanem, Gabrielle Archer, Bruno Crestani, Arnaud A. Mailleux
Pharmacology & Therapeutics.2024; 259: 108669. CrossRef - Elevation of p53 sensitizes obese kidney to adriamycin-induced aberrant lipid homeostasis via repressing HNF4α-mediated FGF21 sensitivity
Jiahao Li, Yufeng Tang, Guangping Lu, Qingbo Liu, Yuanfang Guo, Jie Wang, Mengjie Xiao, Ting Gao, Xiaohui Zhang, Junlian Gu
Journal of Advanced Research.2024;[Epub] CrossRef - Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway
Jun-Kyu Byun, Gwon-Soo Jung
Biochemical and Biophysical Research Communications.2024; 733: 150425. CrossRef - Myostatin regulates energy homeostasis through autocrine- and paracrine-mediated microenvironment communication
Hui Wang, Shanshan Guo, Huanqing Gao, Jiyang Ding, Hongyun Li, Xingyu Kong, Shuang Zhang, Muyang He, Yonghao Feng, Wei Wu, Kexin Xu, Yuxuan Chen, Hanyin Zhang, Tiemin Liu, Xingxing Kong
Journal of Clinical Investigation.2024;[Epub] CrossRef - The Potential Protective Mechanisms of Exercise-Responsive Molecules in Chronic Kidney Disease
Jae Seung Chang
Exercise Science.2024; 33(4): 366. CrossRef - Timosaponin BII inhibits TGF‐β mediated epithelial‐mesenchymal transition through Smad‐dependent pathway during pulmonary fibrosis
Dali Ding, Xuebin Shen, Lizhen Yu, Yueyue Zheng, Yao Liu, Wei Wang, Li Liu, Zitong Zhao, Sihui Nian, Limin Liu
Phytotherapy Research.2023; 37(7): 2787. CrossRef - Fibroblast growth factors (FGFs) endocrines et fibrogenèse pulmonaire
M. Ghanem, A. Mailleux, B. Crestani
Revue des Maladies Respiratoires.2023; 40(3): 239. CrossRef - Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges
Fukun Chen, NaNa Chen, Chunjuan Xia, Hongyue Wang, Lishi Shao, Chen Zhou, Jiaping Wang
Cell Transplantation.2023;[Epub] CrossRef - MicroRNA functional metal-organic framework nanocomposite for efficient inhibition of drug-resistant breast cancer cells
Yuxin Shen, Yao Zhang, Xiyue Gao, Mengdi Shang, Yanfei Cai, Zhaoqi Yang
Emergent Materials.2023; 6(5): 1537. CrossRef - Downregulation of a potential therapeutic target NPAS2, regulated by p53, alleviates pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via suppressing HES1
Yingying Chen, Zhong He, Bo Zhao, Rui Zheng
Cellular Signalling.2023; 109: 110795. CrossRef - KLF5/MDM2 Axis Modulates Oxidative Stress and Epithelial-Mesenchymal Transition in Human Lens Epithelial Cells: The Role in Diabetic Cataract
Xiao Li, Doudou Chen, Bowen Ouyang, Shengnan Wang, Yawei Li, Li Li, Siquan Zhu, Guangying Zheng
Laboratory Investigation.2023; 103(11): 100226. CrossRef - Exploring the pathogenesis of type 2 diabetes mellitus intestinal damp-heat syndrome and the therapeutic effect of Gegen Qinlian Decoction from the perspective of exosomal miRNA
LiSha He, Tingting Bao, Yingying Yang, Han Wang, Chengjuan Gu, Jia Chen, Tiangang Zhai, Xinhui He, Mengyi Wu, Linhua Zhao, Xiaolin Tong
Journal of Ethnopharmacology.2022; 285: 114786. CrossRef - Cardamomin protects from diabetes-induced kidney damage through modulating PI3K/AKT and JAK/STAT signaling pathways in rats
Chan Gao, Xiao Fei, Ming Wang, Qi Chen, Ning Zhao
International Immunopharmacology.2022; 107: 108610. CrossRef - Fibroblast Growth Factor 21 Predicts Short-Term Prognosis in Patients With Acute Heart Failure: A Prospective Cohort Study
Guihai Wu, Shenglin Wu, Jingyi Yan, Shanshan Gao, Jinxiu Zhu, Minghui Yue, Zexin Li, Xuerui Tan
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef - Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases
Min-Qi Jia, Cha-Xiang Guan, Jia-Hao Tao, Yong Zhou, Liang-Jun Yan
Oxidative Medicine and Cellular Longevity.2022; 2022: 1. CrossRef - Circ_FOXP1 promotes the growth and survival of high glucose-treated human trophoblast cells through the regulation of miR-508-3p/SMAD family member 2 pathway
Mingqun Li, Yuqin Huang, Hongli Xi, Wei Zhang, Ziwu Xiang, Lingyun Wang, Xuanyu Li, Hongyan Guo
Endocrine Journal.2022; 69(9): 1067. CrossRef - Fibroblast growth factor 21 attenuates the progression of hyperuricemic nephropathy through inhibiting inflammation, fibrosis and oxidative stress
Xinghao Jiang, Qing Wu, Yeboah Kwaku Opoku, Yimeng Zou, Dan Wang, Changhui Hu, Guiping Ren
Basic & Clinical Pharmacology & Toxicology.2022; 131(6): 474. CrossRef - Myokines: Novel therapeutic targets for diabetic nephropathy
Ming Yang, Shilu Luo, Jinfei Yang, Wei Chen, Liyu He, Di Liu, Li Zhao, Xi Wang
Frontiers in Endocrinology.2022;[Epub] CrossRef - Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk
Songling Jiang, Dal-Seok Oh, Debra Dorotea, Eunjung Son, Dong-Seon Kim, Hunjoo Ha
Phytomedicine.2021; 80: 153393. CrossRef - Chromatin accessibility of kidney tubular cells under stress reveals key transcription factor mediating acute and chronic kidney disease
Yuexian Xing, Qi Wang, Jing Zhang, Wenju Li, Aiping Duan, Jingping Yang, Zhihong Liu
The FEBS Journal.2021; 288(18): 5446. CrossRef - Small molecules against the origin and activation of myofibroblast for renal interstitial fibrosis therapy
Ya-long Feng, Wen-bo Wang, Yue Ning, Hua Chen, Pei Liu
Biomedicine & Pharmacotherapy.2021; 139: 111386. CrossRef - FGF21 prevents low-protein diet-induced renal inflammation in aged mice
Han Fang, Sujoy Ghosh, Landon C. Sims, Kirsten P. Stone, Cristal M. Hill, Denisha Spires, Daria V. Ilatovskaya, Christopher D. Morrison, Thomas W. Gettys, Krisztian Stadler
American Journal of Physiology-Renal Physiology.2021; 321(3): F356. CrossRef - IFN-α-2b Inhibits the Proliferation and Migration of Fibroblasts via the TGFβ/Smad Signaling Pathway to Reduce Postoperative Epidural Fibrosis
Zhendong Liu, Hui Chen, Zhehao Fan, Jihang Dai, Yu Sun, Lianqi Yan, Rui Wang, Xiaolei Li, Jingcheng Wang
Journal of Interferon & Cytokine Research.2021; 41(8): 271. CrossRef - FOXN3 inhibits cell proliferation and invasion via modulating the AKT/MDM2/p53 axis in human glioma
Chaojia Wang, Hanjun Tu, Ling Yang, Chunming Ma, Juntao Hu, Jie Luo, Hui Wang
Aging.2021; 13(17): 21587. CrossRef - Regulation and Potential Biological Role of Fibroblast Growth Factor 21 in Chronic Kidney Disease
Xue Zhou, Yuefeng Zhang, Ning Wang
Frontiers in Physiology.2021;[Epub] CrossRef - The Multiple Roles of Fibroblast Growth Factor in Diabetic Nephropathy
Junyu Deng, Ye Liu, Yiqiu Liu, Wei Li, Xuqiang Nie
Journal of Inflammation Research.2021; Volume 14: 5273. CrossRef - Exercise Training Alleviates Cardiac Fibrosis through Increasing Fibroblast Growth Factor 21 and Regulating TGF-β1-Smad2/3-MMP2/9 Signaling in Mice with Myocardial Infarction
Yixuan Ma, Yixin Kuang, Wenyan Bo, Qiaoqin Liang, Wenfei Zhu, Mengxin Cai, Zhenjun Tian
International Journal of Molecular Sciences.2021; 22(22): 12341. CrossRef - Snai1-induced partial epithelial–mesenchymal transition orchestrates p53–p21-mediated G2/M arrest in the progression of renal fibrosis via NF-κB-mediated inflammation
Ruochen Qi, Jiyan Wang, Yamei Jiang, Yue Qiu, Ming Xu, Ruiming Rong, Tongyu Zhu
Cell Death & Disease.2021;[Epub] CrossRef - Destruction of the blood-retina barrier in diabetic retinopathy depends on angiotensin-converting enzyme-mediated TGF-β1/Smad signaling pathway activation
Ping Sun, Ning Xu, Yan Li, Yang Han
International Immunopharmacology.2020; 85: 106686. CrossRef Chrysophanol Inhibits the Progression of Diabetic Nephropathy via Inactivation of TGF-β Pathway
Chuan Guo, Yarong Wang, Yuanlin Piao, Xiangrong Rao, Dehai Yin
Drug Design, Development and Therapy.2020; Volume 14: 4951. CrossRef
- RhFGF21 protected PC12 cells against mitochondrial apoptosis triggered by H2O2 via the AKT-mediated ROS signaling pathway
- Complications
- Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome
- Jung Beom Seo, Yeon-Kyung Choi, Hye-In Woo, Yun-A Jung, Sungwoo Lee, Seunghyeong Lee, Mihyang Park, In-Kyu Lee, Gwon-Soo Jung, Keun-Gyu Park
- Diabetes Metab J. 2019;43(6):830-839. Published online March 5, 2019
- DOI: https://doi.org/10.4093/dmj.2018.0181
- 7,020 View
- 145 Download
- 31 Web of Science
- 31 Crossref
-
Abstract
PDFPubReader
Background The hypoglycemic drugs dipeptidyl peptidase-4 (DPP-4) inhibitors have proven protective effects on diabetic kidney disease, including renal fibrosis. Although NOD-like receptor protein 3 (NLRP3) inflammasome activation is known to play an important role in the progression of renal fibrosis, the impact of DPP-4 inhibition on NLRP3-mediated inflammation while ameliorating renal fibrosis has not been fully elucidated. Here, we report that the renoprotective effect of gemigliptin is associated with a reduction in NLRP3-mediated inflammation in a murine model of renal fibrosis.
Methods We examined the effects of gemigliptin on renal tubulointerstitial fibrosis induced in mice by unilateral ureteral obstruction (UUO). Using immunohistochemical and Western blot analysis, we quantitated components of the NLRP3 inflammasome in kidneys with and without gemigliptin treatment, and
in vitro in human kidney tubular epithelial human renal proximal tubule cells (HK-2) cells, we further analyzed the effect of gemigliptin on transforming growth factor-β (TGF-β)-stimulated production of profibrotic proteins.Results Immunohistological examination revealed that gemigliptin ameliorated UUO-induced tubular atrophy and renal fibrosis. Gemigliptin-treated kidneys showed a reduction in levels of NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, and interleukin-1β, which had all been markedly increased by UUO. In line with the
in vivo Conclusion The present study shows that activation of the NLRP3 inflammasome contributes to UUO-induced renal fibrosis and the renoprotective effect of gemigliptin is associated with attenuation of NLRP3 inflammasome activation.
-
Citations
Citations to this article as recorded by- TLR4 Inhibitor TAK‐242 Protected Henoch–Schonlein Purpura Nephritis in Rats by Regulating Inflammatory Response and Immune Competence via NF‐ κB/NLRP3 Signalling
Yirong Liu, Qiong Wu, Zhenxing Huang, Dongmei Zhou, Chao Cai, Wenliang Luo, Ping Feng
Clinical and Experimental Pharmacology and Physiology.2025;[Epub] CrossRef - Novel pharmacological interventions for diabetic kidney disease
Seng Kiong Tan, Jairo A. Pinzon-Cortes, Mark E. Cooper
Current Opinion in Nephrology & Hypertension.2024; 33(1): 13. CrossRef - Integrated analysis reveals crosstalk between pyroptosis and immune regulation in renal fibrosis
Fengxia Bai, Longchao Han, Jifeng Yang, Yuxiu Liu, Xiangmeng Li, Yaqin Wang, Ruijian Jiang, Zhaomu Zeng, Yan Gao, Haisong Zhang
Frontiers in Immunology.2024;[Epub] CrossRef - Di (2-ethylhexyl) phthalate and polystyrene microplastics co-exposure caused oxidative stress to activate NF-κB/NLRP3 pathway aggravated pyroptosis and inflammation in mouse kidney
Shanshan Li, Xuedie Gu, Muyue Zhang, Qihang Jiang, Tong Xu
Science of The Total Environment.2024; 926: 171817. CrossRef - Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation
Linfeng Zheng, Wenjuan Mei, Jing Zhou, Xin Wei, Zhijuan Huang, Xiaozhen Lin, Li Zhang, Wei Liu, Qian Wu, Jinhong Li, Yan Yan
Experimental and Therapeutic Medicine.2024;[Epub] CrossRef - Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway
Jun-Kyu Byun, Gwon-Soo Jung
Biochemical and Biophysical Research Communications.2024; 733: 150425. CrossRef - Uncovering the Role of Anoikis-Related Genes in Modulating Immune Infiltration and Pathogenesis of Diabetic Kidney Disease
Jiaqiong Lin, Yan Lin, Xiaoyong Li, Fei He, Qinyuan Gao, Yuanjun Wang, Zena Huang, Fu Xiong
Journal of Inflammation Research.2024; Volume 17: 4975. CrossRef - Activation of NLRP3 inflammasome in patients with renal transplantation: relation to allograft dysfunction, inflammation, and renal fibrosis
Hayam Abdel Meguid El Aggan, Hala Saddik El-Wakil, Sabah Abdel-Hady Mahmoud, Aya Ahmad Saad
Alexandria Journal of Medicine.2024; 60(1): 249. CrossRef - Therapy Targeted to the NLRP3 Inflammasome in Chronic Kidney Disease
Yong Ji, Hu Hua, Zhanjun Jia, Aihua Zhang, Guixia Ding
Kidney Diseases.2024; 10(5): 369. CrossRef - Evaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats
Jorge Morones, Mariana Pérez, Martín Muñoz, Esperanza Sánchez, Manuel Ávila, Jorge Topete, Javier Ventura, Sandra Martínez
International Journal of Molecular Sciences.2024; 25(21): 11372. CrossRef - Regulated cell death in chronic kidney disease: current evidence and future clinical perspectives
Kurt T. K. Giuliani, Benjamin C. Adams, Helen G. Healy, Andrew J. Kassianos
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef - HIF1α-BNIP3-mediated mitophagy protects against renal fibrosis by decreasing ROS and inhibiting activation of the NLRP3 inflammasome
Jialin Li, Qisheng Lin, Xinghua Shao, Shu Li, Xuying Zhu, Jingkui Wu, Shan Mou, Leyi Gu, Qin Wang, Minfang Zhang, Kaiqi Zhang, Jiayue Lu, Zhaohui Ni
Cell Death & Disease.2023;[Epub] CrossRef - Pyroptosis in renal inflammation and fibrosis: current knowledge and clinical significance
Ya Liu, Haibo Lei, Wenyou Zhang, Qichang Xing, Renzhu Liu, Shiwei Wu, Zheng Liu, Qingzi Yan, Wencan Li, Xiang Liu, Yixiang Hu
Cell Death & Disease.2023;[Epub] CrossRef - Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives
Yu Wang, Mingyue Jin, Chak Kwong Cheng, Qiang Li
Frontiers in Endocrinology.2023;[Epub] CrossRef - Hederagenin inhibits high glucose‐induced fibrosis in human renal cells by suppression of NLRP3 inflammasome activation through reducing cathepsin B expression
Guohua Yang, Wang Yang, Hairong Jiang, Qing Yi, Wei Ma
Chemical Biology & Drug Design.2023; 102(6): 1409. CrossRef - Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis
Rikke Nørregaard, Henricus A. M. Mutsaers, Jørgen Frøkiær, Tae-Hwan Kwon
Physiological Reviews.2023; 103(4): 2847. CrossRef - Adenine model of chronic renal failure in rats to determine whether MCC950, an NLRP3 inflammasome inhibitor, is a renopreventive
Mahmoud S. Sabra, Fahmy K. Hemida, Essmat A. H. Allam
BMC Nephrology.2023;[Epub] CrossRef - Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome
Yun Zhang, Song Zhang, Bolin Li, Yingchun Luo, Yongtai Gong, Xuexin Jin, Jiawei Zhang, Yun Zhou, Xiaozhen Zhuo, Zixi Wang, Xinbo Zhao, Xuejie Han, Yunlong Gao, Hui Yu, Desen Liang, Shiqi Zhao, Danghui Sun, Dingyu Wang, Wei Xu, Guangjin Qu, Wanlan Bo, Dan
Cardiovascular Research.2022; 118(3): 785. CrossRef - The NLRP3 inflammasome in fibrosis and aging: The known unknowns
Yanqing Liu, Xuezeng Xu, Wangrui Lei, Yuxuan Hou, Yan Zhang, Ran Tang, Zhi Yang, Ye Tian, Yanli Zhu, Changyu Wang, Chao Deng, Shaofei Zhang, Yang Yang
Ageing Research Reviews.2022; 79: 101638. CrossRef - Research progress of endothelial‐mesenchymal transition in diabetic kidney disease
Ying Chen, Hang Zou, Hongwei Lu, Hong Xiang, Shuhua Chen
Journal of Cellular and Molecular Medicine.2022; 26(12): 3313. CrossRef - Exploring the mechanism of Shendi Bushen capsule in anti-renal fibrosis using metabolomics theory and network analysis
Tianwei Meng, Hong Chang, Hongyu Meng
Molecular Omics.2022; 18(9): 873. CrossRef - Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats
Wan Seok Kang, Woo Kwon Jung, Su-Bin Park, Hyung Rae Kim, Junghyun Kim
Biomedicine & Pharmacotherapy.2021; 137: 111297. CrossRef - Long‐Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats
Edwin K. Jackson, Zaichuan Mi, Delbert G. Gillespie, Dongmei Cheng, Stevan P. Tofovic
Journal of the American Heart Association.2021;[Epub] CrossRef - Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis
Yu Zhang, Ruicheng Zhang, Xiaohu Han
Inflammation Research.2021; 70(5): 543. CrossRef - Inflammasome as an Effective Platform for Fibrosis Therapy
Ting-Ting Chen, Feng Xiao, Nan Li, Shan Shan, Meng Qi, Zi-Ying Wang, Sheng-Nan Zhang, Wei Wei, Wu-Yi Sun
Journal of Inflammation Research.2021; Volume 14: 1575. CrossRef - Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?
Xin Huang, Yimin Khoong, Chengyao Han, Dai Su, Hao Ma, Shuchen Gu, Qingfeng Li, Tao Zan
Frontiers in Physiology.2021;[Epub] CrossRef - Linagliptin Protects against Endotoxin-Induced Acute Kidney Injury in Rats by Decreasing Inflammatory Cytokines and Reactive Oxygen Species
Tsung-Jui Wu, Yi-Jen Hsieh, Chia-Wen Lu, Chung-Jen Lee, Bang-Gee Hsu
International Journal of Molecular Sciences.2021; 22(20): 11190. CrossRef - Psidium guajava Flavonoids Prevent NLRP3 Inflammasome Activation and Alleviate the Pancreatic Fibrosis in a Chronic Pancreatitis Mouse Model
Guixian Zhang, Liming Tang, Hongbin Liu, Dawei Liu, Manxue Wang, Jun Cai, Weijun Liu, Wei Nie, Yi Zhang, Xiaomeng Yu
The American Journal of Chinese Medicine.2021; 49(08): 2001. CrossRef - Effect and Regulation of the NLRP3 Inflammasome During Renal Fibrosis
Hong Zhang, Zhengchao Wang
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef - Zhen-Wu-Tang Protects IgA Nephropathy in Rats by Regulating Exosomes to Inhibit NF-κB/NLRP3 Pathway
Honglian Li, Ruirui Lu, Yu Pang, Jicheng Li, Yiwen Cao, Hongxin Fu, Guoxing Fang, Qiuhe Chen, Bihao Liu, Junbiao Wu, Yuan Zhou, Jiuyao Zhou
Frontiers in Pharmacology.2020;[Epub] CrossRef - Protective effect of exogenous hydrogen sulfide on diaphragm muscle fibrosis in streptozotocin-induced diabetic rats
Rui Yang, Qiang Jia, Yan Li, Shomaila Mehmood
Experimental Biology and Medicine.2020; 245(14): 1280. CrossRef
- TLR4 Inhibitor TAK‐242 Protected Henoch–Schonlein Purpura Nephritis in Rats by Regulating Inflammatory Response and Immune Competence via NF‐ κB/NLRP3 Signalling
- Complication
- Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus
- Eun-Hee Cho, Sang-Wook Kim
- Diabetes Metab J. 2019;43(1):97-104. Published online October 8, 2018
- DOI: https://doi.org/10.4093/dmj.2018.0030
- 5,786 View
- 63 Download
- 14 Web of Science
- 16 Crossref
-
Abstract
PDFPubReader
Background Dipeptidyl peptidase-4 (DPP-4) is strongly expressed in the kidney, and soluble levels of this protein are used as a marker in various chronic inflammatory diseases, including diabetes, coronary artery disease, and cancer. This study examined the association between the serum soluble DPP-4 levels and renal function or cardiovascular risk in patients with type 2 diabetes mellitus.
Methods In this retrospective analysis, soluble DPP-4 levels were measured in preserved sera from 140 patients with type 2 diabetes mellitus who had participated in our previous coronary artery calcium (CAC) score study.
Results The mean±standard deviation soluble DPP-4 levels in our study sample were 645±152 ng/mL. Univariate analyses revealed significant correlations of soluble DPP-4 levels with the total cholesterol (
r =0.214,P =0.019) and serum creatinine levels (r =−0.315,P <0.001) and the estimated glomerular filtration rate (eGFR; estimated using the modification of diet in renal disease equation) (r =0.303,P =0.001). The associations of soluble DPP-4 levels with serum creatinine and GFR remained significant after adjusting for age, body mass index, and duration of diabetes. However, no associations were observed between soluble DPP-4 levels and the body mass index, waist circumference, or CAC score.Conclusion These data suggest the potential use of serum soluble DPP-4 levels as a future biomarker of deteriorated renal function in patients with type 2 diabetes mellitus.
-
Citations
Citations to this article as recorded by- Factors Involved in the Development of Diabetic Kidney Disease in Patients With Slowly Progressive Type 1 Diabetes Mellitus: A Retrospective Cohort Study
Hideyuki Okuma, Takahiro Tsutsumi, Masashi Ichijo, Tetsuro Kobayashi, Kyoichiro Tsuchiya
Cureus.2024;[Epub] CrossRef - SIGNIFICANCE OF URINARY AMINOPEPTIDASE N AND DIPEPTIDYL PEPTIDASE IV IN EARLY DIAGNOSIS OF KIDNEY DAMAGE IN CHILDREN WITH TYPE 1 DIABETES MELLITUS IN NORTH-EASTERN REGION OF UKRAINE
Iryna Vikhrova, Andrii Loboda, Igor Zmyslia
Eastern Ukrainian Medical Journal.2024; 12(4): 808. CrossRef - Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway
Sarah M. AL-Qabbaa, Samaher I. Qaboli, Tahani K. Alshammari, Maha A. Alamin, Haya M. Alrajeh, Lama A. Almuthnabi, Rana R. Alotaibi, Asma S. Alonazi, Anfal F. Bin Dayel, Nawal M. Alrasheed, Nouf M. Alrasheed
International Journal of Molecular Sciences.2023; 24(7): 6532. CrossRef - Evaluation of the efficacy of dipeptidyl peptidase-4 enzyme and selenium element in people with kidney failure in Kirkuk governorate
Ibrahim Abdullah Ali Al-Jubouri, Nadia Ahmed Saleh Al-Jubouri
Materials Today: Proceedings.2022; 60: 795. CrossRef - Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials
John R. Ussher, Amanda A. Greenwell, My-Anh Nguyen, Erin E. Mulvihill
Diabetes.2022; 71(2): 173. CrossRef - Computer-Aided Screening of Phytoconstituents from Ocimum tenuiflorum against Diabetes Mellitus Targeting DPP4 Inhibition: A Combination of Molecular Docking, Molecular Dynamics, and Pharmacokinetics Approaches
Harshit Sajal, Shashank M. Patil, Ranjith Raj, Abdullah M. Shbeer, Mohammed Ageel, Ramith Ramu
Molecules.2022; 27(16): 5133. CrossRef - Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022. CrossRef - An update on the interaction between COVID-19, vaccines, and diabetic kidney disease
Yang Yang, Shubiao Zou, Gaosi Xu
Frontiers in Immunology.2022;[Epub] CrossRef - Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171. CrossRef - Renoprotective Effects of DPP-4 Inhibitors
Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, Ryoko Motonaga, Makito Tanabe
Antioxidants.2021; 10(2): 246. CrossRef - Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with signif
Masaaki Sagara, Toshie Iijima, Masato Kase, Kanako Kato, Shintaro Sakurai, Takuya Tomaru, Teruo Jojima, Isao Usui, Yoshimasa Aso
Journal of Diabetes and its Complications.2021; 35(5): 107885. CrossRef - Distinctive CD26 Expression on CD4 T-Cell Subsets
Oscar J. Cordero, Carlos Rafael-Vidal, Rubén Varela-Calviño, Cristina Calviño-Sampedro, Beatriz Malvar-Fernández, Samuel García, Juan E. Viñuela, José M. Pego-Reigosa
Biomolecules.2021; 11(10): 1446. CrossRef - The Long-Term Study of Urinary Biomarkers of Renal Injury in Spontaneously Hypertensive Rats
Sebastián Montoro-Molina, Andrés Quesada, Francisco O’Valle, Natividad Martín Morales, María del Carmen de Gracia, Isabel Rodríguez-Gómez, Antonio Osuna, Rosemary Wangensteen, Félix Vargas
Kidney and Blood Pressure Research.2021; 46(4): 502. CrossRef - Assessment of retinol-binding protein-4, fibroblast growth factor-21, and dipeptidyl peptidase-4 in relation to obesity and insulin resistance of type 2 diabetes mellitus among Egyptian patients
Ayat I. Ghanem, Atef A. Bassyouni, Ghada A. Omar
Journal of The Arab Society for Medical Research.2021; 16(1): 32. CrossRef - Serum Dipeptidyl peptidase-4 level is related to adiposity in type 1 diabetic adolescents
Amany Ibrahim, Shaimaa Salah, Mona Attia, Hanan Madani, Samah Ahmad, Noha Arafa, Hend Soliman
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(4): 609. CrossRef - Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma
Masayuki Takeda, Yuichiro Ohe, Hidehito Horinouchi, Toyoaki Hida, Junichi Shimizu, Takashi Seto, Kaname Nosaki, Takumi Kishimoto, Itaru Miyashita, Masayuki Yamada, Yutaro Kaneko, Chikao Morimoto, Kazuhiko Nakagawa
Lung Cancer.2019; 137: 64. CrossRef
- Factors Involved in the Development of Diabetic Kidney Disease in Patients With Slowly Progressive Type 1 Diabetes Mellitus: A Retrospective Cohort Study
- Obesity and Metabolic Syndrome
- Associations between Body Mass Index and Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients: Findings from the Northeast of Thailand
- Sojib Bin Zaman, Naznin Hossain, Muntasirur Rahman
- Diabetes Metab J. 2018;42(4):330-337. Published online August 21, 2018
- DOI: https://doi.org/10.4093/dmj.2017.0052
- 5,636 View
- 70 Download
- 11 Web of Science
- 15 Crossref
-
Abstract
PDFPubReader
Background Chronic kidney disease (CKD) has emerged as a public health burden globally. Obesity and long-term hyperglycaemia can initiate the renal vascular complications in patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the association of body mass index (BMI) with the CKD in patients with T2DM.
Methods This study has used retrospective medical records, biochemical reports, and anthropometric measurements of 3,580 T2DM patients which were collected between January to December 2015 from a district hospital in Thailand. CKD was defined according to the measurement of estimated glomerular filtration rate (<60 mL/min/1.73 m2). Multiple logistic regression analysis was used to explore the association between BMI and CKD in patients with T2DM.
Results The mean age of the participants was 60.86±9.67 years, 53.68% had poor glycaemic control, and 45.21% were overweight. About one-in-four (23.26%) T2DM patients had CKD. The mean BMI of non-CKD group was slightly higher (25.30 kg/m2 vs. 24.30 kg/m2) when compared with CKD patients. Multivariable analysis showed that older age, female sex, hypertension, and microalbuminuria were associated with the presence of CKD. No association was observed between CKD and poorly controlled glycosylated hemoglobin or hypercholesterolemia. Adjusted analysis further showed overweight and obesity were negatively associated with CKD (adjusted odds ratio [AOR], 0.73; 95% confidence interval [CI], 0.58 to 0.93) and (AOR, 0.53; 95% CI, 0.35 to 0.81), respectively.
Conclusion The negative association of BMI with CKD could reflect the reverse causality. Lower BMI might not lead a diabetic patient to develop CKD, but there are possibilities that CKD leads the patient to experience reduced BMI.
-
Citations
Citations to this article as recorded by- Weight fluctuation and incidence of end-stage renal disease in Korea: a nationwide cohort study
Koh-Eun Shin, Byoungduck Han, Gyu Bae Lee, Jihyun Yoon, Kyungdo Han, Yang-Hyun Kim
Cardiovascular Prevention and Pharmacotherapy.2025; 7(2): 28. CrossRef - Increased Body Mass Index is Independently Associated with Chronic Kidney Disease among People with Type 2 Diabetes
Vijay Viswanathan, Sivashankari SelvaElavarasan, Satyavani Kumpatla
Indian Journal of Nephrology.2024; 0: 1. CrossRef - Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis
Eneyew Talie Fenta, Habitu Birhan Eshetu, Natnael Kebede, Eyob Ketema Bogale, Amare Zewdie, Tadele Derbew Kassie, Tadele Fentabil Anagaw, Elyas Melaku Mazengia, Sintayehu Shiferaw Gelaw
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef - Risk Factors of Chronic Kidney Disease (CKD) in Type 2 Diabetes Mellitus (DM) Patients at Dr. Soetomo General Academic Hospital, Surabaya
Joshua Teofilus Sutadji, Agung Pranoto, Risky Vitria Prasetyo
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga.2023; 14(1): 12. CrossRef - Profile of Obesity and Comorbidities and their Correlation among Hemodialysis Patients, Elbasan
Brunilda Elezi, Skender Topi, Erjona Abazaj
Open Access Macedonian Journal of Medical Sciences.2022; 10(E): 225. CrossRef - Association of eNOS and MCP-1 Genetic Variants with Type 2 Diabetes and Diabetic Nephropathy Susceptibility: A Case–Control and Meta-Analysis Study
Priyanka Raina, Ruhi Sikka, Himanshu Gupta, Kawaljit Matharoo, Surinder Kumar Bali, Virinder Singh, AJS Bhanwer
Biochemical Genetics.2021; 59(4): 966. CrossRef - New Pandemic: Obesity and Associated Nephropathy
Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
Frontiers in Medicine.2021;[Epub] CrossRef - Associations between obesity, weight change and decreased renal function in Korean type 2 diabetic patients: a longitudinal follow-up study
Bo-Yeon Kim, Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim
BMC Endocrine Disorders.2021;[Epub] CrossRef - The burden of chronic kidney disease among people with diabetes by insurance schemes: Findings from a primary referral hospital in Thailand
Sojib Bin Zaman, Rajat Das Gupta, Putthikrai Pramual, Raihan Kabir Khan, Chinakorn Sujimongkol, Naznin Hossain, Mohammad Rifat Haider, Md. Nazmul Karim, Gulam Muhammed Kibria, Sheikh Mohammdad Shariful Islam
Diabetes Epidemiology and Management.2021; 4: 100026. CrossRef - Association between body mass index and estimated glomerular filtration rate in patients with chronic kidney disease of unknown aetiology in Sri Lanka
M. R. D. L. Kulathunga, M. A. A. Wijayawardena, Ravi Naidu, S. J. Wimalawansa, A. W. Wijeratne
Environmental Geochemistry and Health.2020; 42(9): 2645. CrossRef - The prevalence of diabetic chronic kidney disease in adult Greek subjects with type 2 diabetes mellitus: A series from hospital-based diabetes clinics
Ilias N. Migdalis, Nikolaos Papanas, Athanasios E. Raptis, Ioannis M. Ioannidis, Alexios E. Sotiropoulos, George D. Dimitriadis
Diabetes Research and Clinical Practice.2020; 166: 108243. CrossRef - Underweight Increases the Risk of End-Stage Renal Diseases for Type 2 Diabetes in Korean Population: Data From the National Health Insurance Service Health Checkups 2009–2017
Yang-Hyun Kim, Jun Goo Kang, Seong Jin Lee, Kyung-do Han, Sung-Hee Ihm, Kyung-Hwan Cho, Yong-Gyu Park
Diabetes Care.2020; 43(5): 1118. CrossRef - Prevalence and risk factors of chronic kidney disease among Palestinian type 2 diabetic patients: a cross-sectional study
Zaher Nazzal, Zakaria Hamdan, Dunia Masri, Oday Abu-Kaf, Mohammad Hamad
BMC Nephrology.2020;[Epub] CrossRef - Effects of Variability in Blood Pressure, Glucose, and Cholesterol Concentrations, and Body Mass Index on End-Stage Renal Disease in the General Population of Korea
Mee Kyoung Kim, Kyungdo Han, Hun-Sung Kim, Yong-Moon Park, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
Journal of Clinical Medicine.2019; 8(5): 755. CrossRef - Obese First degree relatives of hemodialysis patients are at Higher Risk for Developing Kidney Diseases: In a Cross-sectional Study
Abozaid Mohammed Elemam
Sudan Journal of Medical Sciences.2019; 14(3): 143. CrossRef
- Weight fluctuation and incidence of end-stage renal disease in Korea: a nationwide cohort study
- Complications
- Glycated Albumin Is a More Useful Glycation Index than HbA1c for Reflecting Renal Tubulopathy in Subjects with Early Diabetic Kidney Disease
- Ji Hye Huh, Minyoung Lee, So Young Park, Jae Hyeon Kim, Byung-Wan Lee
- Diabetes Metab J. 2018;42(3):215-223. Published online May 2, 2018
- DOI: https://doi.org/10.4093/dmj.2017.0091
- 5,639 View
- 59 Download
- 10 Web of Science
- 10 Crossref
-
Abstract
PDFPubReader
Background The aim of this study was to investigate which glycemic parameters better reflect urinary N-acetyl-β-D-glucosaminidase (uNAG) abnormality, a marker for renal tubulopathy, in subjects with type 2 diabetes mellitus (T2DM) subjects with normoalbuminuria and a normal estimated glomerular filtration rate (eGFR).
Methods We classified 1,061 participants with T2DM into two groups according to uNAG level—normal vs. high (>5.8 U/g creatinine)—and measured their biochemical parameters.
Results Subjects with high uNAG level had significantly higher levels of fasting and stimulated glucose, glycated albumin (GA), and glycosylated hemoglobin (HbA1c) and lower levels of homeostasis model assessment of β-cell compared with subjects with normal uNAG level. Multiple linear regression analyses showed that uNAG was significantly associated with GA (standardized β coefficient [β]=0.213,
P =0.016), but not with HbA1c (β=−0.137,P =0.096) or stimulated glucose (β=0.095,P =0.140) after adjusting confounding factors. In receiver operating characteristic analysis, the value of the area under the curve (AUC) for renal tubular injury of GA was significantly higher (AUC=0.634; 95% confidence interval [CI], 0.646 to 0.899) than those for HbA1c (AUC=0.598; 95% CI, 0.553 to 0.640), stimulated glucose (AUC=0.594; 95% CI, 0.552 to 0.636), or fasting glucose (AUC=0.558; 95% CI, 0.515 to 0.600). The optimal GA cutoff point for renal tubular damage was 17.55% (sensitivity 59%, specificity 62%).Conclusion GA is a more useful glycation index than HbA1c for reflecting renal tubulopathy in subjects with T2DM with normoalbuminuria and normal eGFR.
-
Citations
Citations to this article as recorded by- Glucagon-Like Peptide 1 Receptor Agonist Improves Renal Tubular Damage in Mice with Diabetic Kidney Disease
Ran Li, Dunmin She, Zhengqin Ye, Ping Fang, Guannan Zong, Yong Zhao, Kerong Hu, Liya Zhang, Sha Lei, Keqin Zhang, Ying Xue
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1331. CrossRef - Use of glycated albumin for the identification of diabetes in subjects from northeast China
Guo-Yan Li, Hao-Yu Li, Qiang Li
World Journal of Diabetes.2021; 12(2): 149. CrossRef - Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada
Journal of Clinical Medicine.2021; 10(9): 2040. CrossRef - Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition
Nitin A. Das, Andrea J. Carpenter, Anthony Belenchia, Annayya R. Aroor, Makoto Noda, Ulrich Siebenlist, Bysani Chandrasekar, Vincent G. DeMarco
Cellular Signalling.2020; 68: 109506. CrossRef - Glycated Plasma Proteins as More Sensitive Markers for Glycemic Control in Type 1 Diabetes
Lina Zhang, Qibin Zhang
PROTEOMICS – Clinical Applications.2020;[Epub] CrossRef - Glycated albumin and its variability: Clinical significance, research progress and overall review
Dongjun Dai, Yifei Mo, Jian Zhou
Obesity Medicine.2020; 19: 100256. CrossRef - Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
Medicine.2020; 99(33): e21038. CrossRef - Increasing waist circumference is associated with decreased levels of glycated albumin
Yiting Xu, Xiaojing Ma, Yun Shen, Yufei Wang, Jian Zhou, Yuqian Bao
Clinica Chimica Acta.2019; 495: 118. CrossRef - Glucometabolic characteristics and higher vascular complication risk in Korean patients with type 2 diabetes with non-albumin proteinuria
Yongin Cho, Yong-ho Lee, Eun Seok Kang, Bong-soo Cha, Byung-wan Lee
Journal of Diabetes and its Complications.2019; 33(8): 585. CrossRef - Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes
Huanhuan Zhu, Xi Liu, Chengning Zhang, Qing Li, Xiaofei An, Simeng Liu, Lin Wu, Bo Zhang, Yanggang Yuan, Changying Xing
Journal of Diabetes and its Complications.2019; 33(11): 107419. CrossRef
- Glucagon-Like Peptide 1 Receptor Agonist Improves Renal Tubular Damage in Mice with Diabetic Kidney Disease
First
Prev
